# Cefepime study flags a dosing risk

> A major review links a common hospital antibiotic to a slightly higher death rate, with dosing emerging as the key concern.
- Title: Cefepime study flags a dosing risk · Fox News | Shortify
- Summary: A major review links a common hospital antibiotic to a slightly higher death rate, with dosing emerging as the key concern. Cefepime is still widely used…
- Keywords: cefepime, antibiotic, jama network open, beta-lactam antibiotics, febrile neutropenia, pneumonia, utis, meningitis, mortality risk, drug dosing, neurotoxicity, marc siegel
- Source: Fox News — https://foxnews.com/health/common-antibiotic-linked-higher-risk-death-adults-major-study-finds
- Author: Angelica Stabile
- Published: 2026-09-15T00:00:00+00:00
- Read time: 1 min
- Topics: cefepime, antibiotic, jama network open, beta-lactam antibiotics, febrile neutropenia, pneumonia, utis, meningitis, mortality risk, drug dosing, neurotoxicity, marc siegel
## A common drug
Cefepime is a broad-spectrum antibiotic used in hospitals for pneumonia, UTIs, skin infections and other serious bacterial infections.

> A commonly used drug has been linked to a higher risk of death in a new study.
## The study pool
Researchers reviewed 110 randomized trials with more than 22,000 patients who received cefepime or another beta-lactam antibiotic.
## A small gap
Deaths within about 30 days occurred in 6.6% of cefepime patients, compared with 6.2% among those given another antibiotic.
## Adults stood out
The mortality link looked stronger in adults than in children, and strongest among patients treated for febrile neutropenia.
## Do not stop it
Researchers did not call for cefepime to be pulled. They said more guidance and research are needed to pin down its safety risks.
## Dose may matter
Too little cefepime may fail to control infection. Too much can raise the risk of toxic side effects, including confusion, low consciousness or seizures.
## Causation is unclear
The review found an association, not proof that cefepime caused more deaths. The trials varied by design, patients, doses and comparison drugs.

> appropriate dosing may be the key
## Key takeaway

Cefepime is still widely used, but patients with serious infections may need closer dosing and safety monitoring, especially adults with febrile neutropenia.